Arrowhead Pharmaceuticals director sells shares valued at $20,139

The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares directly. With the company's next earnings report due on February 10th, InvestingPro subscribers can access 8 additional key insights about Arrowhead's financial position and growth prospects. The sale was executed under a prearranged 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a set time to avoid potential conflicts of interest. This transaction reflects Olukotun's ongoing involvement with the company while adhering to regulatory compliance measures. The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares directly. With the company's next earnings report due on February 10th, InvestingPro subscribers can access 8 additional key insights about Arrowhead's financial position and growth prospects. The sale was executed under a prearranged 10b5-1 trading plan, which allows insiders to sell a predetermined number of shares at a set time to avoid potential conflicts of interest. This transaction reflects Olukotun's ongoing involvement with the company while adhering to regulatory compliance measures.

In other recent news, Sarepta Therapeutics (NASDAQ:SRPT) has secured a partnership with Arrowhead Pharmaceuticals (NASDAQ:ARWR), sparking discussions among investors. BMO Capital Markets has maintained an Outperform rating on Sarepta's shares, anticipating potential clinical data announcements at the upcoming JPMorgan Healthcare Conference. The partnership is expected to bring attention to Sarepta's ARO-DM1 program, deemed to have a 70% probability of demonstrating superior safety and efficacy compared to its competitors.

On the other hand, Arrowhead Pharmaceuticals has entered into a significant strategic partnership with Sarepta Therapeutics, involving a $500 million upfront payment and a $325 million equity investment. This collaboration is expected to support the commercial launch of Arrowhead's first RNA interference (RNAi) therapeutic, anticipated in 2026 if approved.

Analysts from various firms have reacted to these developments. H.C. Wainwright raised Arrowhead's price target, expressing optimism about the company's recent global license and collaboration agreement with Sarepta Therapeutics. Bernstein SocGen Group, however, lowered its price target for Arrowhead due to capital concerns for the plozasiran CAPITAN CVOT trial. Piper Sandler reduced its 12-month price target for Arrowhead but maintained an Overweight rating on the stock. These are just a few of the recent developments in both companies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.